Table 1.
Some examples of nanocarrier-based drugs on the market
| Commercial name | Type of nanoparticle/drug | Area of activity |
|---|---|---|
| Abraxane® | Nanoparticulate albumin/paclitaxel | Several cancers |
| Aurimune® | Colloidal gold/TNF | Solid tumors |
| Combidex® | Iron oxide nanoparticles | Tumor imaging |
| Cyclosert® | Cyclodextrin nanoparticles | Solid tumors |
| Doxil® | PEGylated liposomes/doxorubicin | Ovarian cancer |
| INGN-401® | Liposomal/FUS1 | Lung cancer |
| Megace ES® | Nanocrystal/megestrol acetate | Breast cancer |
| SGT-53® | Liposome TF antibody/p53 gene | Solid tumors |
| Zinostatin/stimalmar® | Polymer-protein conjugate/SMANCS | Hepatocellular carcinoma |
| Oncaspar® | Polymer-protein conjugate/PEG-L-asparaginase | Acute lymphoblastic leukemia |
| DaunoXome® | Liposomes/daunorubicin | Kaposi’s sarcoma |
| Myocet® | Liposomes/doxorubicin | Combinational therapy of breast cancer, ovarian cancer and Kaposi’s sarcoma |
| Onco TCS® | Liposomes/vincristine | Relapsed aggressive non-Hodgkin’s lymphoma |
| Bexxar® | Radioimmunoconjugate/anti-CD20 conjugated to iodine-131 | Relapsed or refractory, low-grade, follicular or transformed non-Hodgkin’s lymphoma |
Abbreviations: PEG, polyethylene glycol; SMANCS, styrene maleic acid neocarzinostatin; TNF, tumor necrosis factor.